In NSCLC, tyrosine kinase inhibitor, immune checkpoint inhibitors, and antibodies against interleukin 6 receptor (IL-6R) have shown antimetastatic effects [52,53,54]. Here, IL6R is linked to non-small cell lung carcinoma.